FR2535609A1 - Medicament a action antitumorale a base de polyhexamethyleneguanidine - Google Patents
Medicament a action antitumorale a base de polyhexamethyleneguanidine Download PDFInfo
- Publication number
- FR2535609A1 FR2535609A1 FR8218494A FR8218494A FR2535609A1 FR 2535609 A1 FR2535609 A1 FR 2535609A1 FR 8218494 A FR8218494 A FR 8218494A FR 8218494 A FR8218494 A FR 8218494A FR 2535609 A1 FR2535609 A1 FR 2535609A1
- Authority
- FR
- France
- Prior art keywords
- cancer
- product
- polyhexamethyleneguanidine
- tumor
- action
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 9
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 5
- 239000010452 phosphate Substances 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 abstract 2
- 239000011149 active material Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 33
- 239000000047 product Substances 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 21
- 201000011510 cancer Diseases 0.000 description 20
- 229940079593 drug Drugs 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 206010006417 Bronchial carcinoma Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- 201000000274 Carcinosarcoma Diseases 0.000 description 3
- 208000001792 Sarcoma 37 Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 208000002847 Surgical Wound Diseases 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000010932 epithelial neoplasm Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 208000007093 Leukemia L1210 Diseases 0.000 description 1
- 208000009033 Leukemia L5178 Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001909 effect on DNA Effects 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SU1982/000020 WO1984000105A1 (fr) | 1982-06-21 | 1982-06-21 | Preparation medicinale ayant un effet antitumoral |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2535609A1 true FR2535609A1 (fr) | 1984-05-11 |
| FR2535609B1 FR2535609B1 (enExample) | 1985-03-15 |
Family
ID=21616776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8218494A Granted FR2535609A1 (fr) | 1982-06-21 | 1982-11-04 | Medicament a action antitumorale a base de polyhexamethyleneguanidine |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS59501110A (enExample) |
| CA (1) | CA1194802A (enExample) |
| CH (1) | CH660964A5 (enExample) |
| DE (1) | DE3249514T1 (enExample) |
| FR (1) | FR2535609A1 (enExample) |
| GB (1) | GB2134783B (enExample) |
| NL (1) | NL8220420A (enExample) |
| SE (1) | SE8400453L (enExample) |
| WO (1) | WO1984000105A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1110948A3 (en) * | 1999-12-20 | 2002-01-09 | SK Corporation | Polyhexamethyleneguanidine phosphate powder, method of making the same and antimicrobial resin containing the same |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5344846A (en) * | 1992-12-30 | 1994-09-06 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells |
| DE19628641C2 (de) * | 1996-07-16 | 1998-12-17 | Fresenius Ag | Verwendung von PHMB zur Behandlung von Tumorerkrankungen |
| RU2144024C1 (ru) * | 1998-10-28 | 2000-01-10 | Иркутский институт химии СО РАН | Способ получения фосфата полигексаметиленгуанидина |
| KR100725004B1 (ko) * | 1999-12-24 | 2007-06-04 | 에스케이 주식회사 | 살균소독제 조성물 및 이의 사용방법 |
| AT505312A1 (de) | 2007-05-15 | 2008-12-15 | Recticel Schlafkomfort Gmbh Sc | Polyurethan-werkstoff mit einer bioziden ausrüstung |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5341426A (en) * | 1976-09-27 | 1978-04-14 | Asahi Chem Ind Co Ltd | Fungicidal and bactericidal agents |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3824288A (en) * | 1961-06-09 | 1974-07-16 | Hoffmann La Roche | Substituted hydrazine derivatives and process for the manufacture thereof |
| BR6457241D0 (pt) * | 1963-12-23 | 1973-06-26 | Rohm & Haas | Processo para a preparacao de t-octil-guanidinas |
| GB1492678A (en) * | 1975-08-11 | 1977-11-23 | Ici Ltd | Guanidine derivatives |
-
1982
- 1982-06-21 DE DE19823249514 patent/DE3249514T1/de not_active Withdrawn
- 1982-06-21 JP JP57503491A patent/JPS59501110A/ja active Pending
- 1982-06-21 CH CH90284A patent/CH660964A5/de not_active IP Right Cessation
- 1982-06-21 GB GB08403257A patent/GB2134783B/en not_active Expired
- 1982-06-21 NL NL8220420A patent/NL8220420A/nl not_active Application Discontinuation
- 1982-06-21 WO PCT/SU1982/000020 patent/WO1984000105A1/ru not_active Ceased
- 1982-10-07 CA CA000413032A patent/CA1194802A/en not_active Expired
- 1982-11-04 FR FR8218494A patent/FR2535609A1/fr active Granted
-
1984
- 1984-01-30 SE SE8400453A patent/SE8400453L/ not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5341426A (en) * | 1976-09-27 | 1978-04-14 | Asahi Chem Ind Co Ltd | Fungicidal and bactericidal agents |
Non-Patent Citations (1)
| Title |
|---|
| CHEMICAL ABSTRACTS, vol. 89, no. 19, 6 novembre 1978, page 175, résumé no. 158758a COLUMBUS OHIO (US) & JP - A - 78 41 426 (ASAHI CHEMICAL INDUSTRY CO. LTD.)(14-04-1978) * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1110948A3 (en) * | 1999-12-20 | 2002-01-09 | SK Corporation | Polyhexamethyleneguanidine phosphate powder, method of making the same and antimicrobial resin containing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| SE437931B (sv) | 1985-03-25 |
| CA1194802A (en) | 1985-10-08 |
| GB2134783B (en) | 1985-10-30 |
| JPS59501110A (ja) | 1984-06-28 |
| GB2134783A (en) | 1984-08-22 |
| DE3249514T1 (de) | 1984-05-17 |
| WO1984000105A1 (fr) | 1984-01-19 |
| SE8400453L (sv) | 1985-03-25 |
| SE8400453D0 (sv) | 1984-01-30 |
| CH660964A5 (de) | 1987-06-30 |
| GB8403257D0 (en) | 1984-03-14 |
| NL8220420A (nl) | 1984-05-01 |
| FR2535609B1 (enExample) | 1985-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101888779B1 (ko) | Ａｍｐｋ 활성을 증진시킬 수 있는 약물을 제조하기 위한 이소퀴놀린 알칼로이드 유도체의 용도 | |
| CN114940679A (zh) | Sting激动剂前药化合物及其制备方法和应用 | |
| JP6209579B2 (ja) | 補助化療薬品とされる医薬組成物その用途 | |
| CA2522980A1 (en) | Water soluble wortmannin derivatives | |
| FR2535609A1 (fr) | Medicament a action antitumorale a base de polyhexamethyleneguanidine | |
| FR2684381A1 (fr) | Composes presentant une liaison amide phosphorique ou une liaison phosphate d'enol pour leur application en tant que substance therapeutiquement active. | |
| FR3002451A1 (fr) | Heterocycles phosphores analogues de sucres a activite antimetastatique | |
| FR2601678A1 (fr) | Peptides comprenant la sequence seryl-aspartyl-lysyl-prolyle, procede pour l'extraction du tetrapeptide correspondant, et applications, notamment a la protection de la moelle osseuse au cours de traitements anticancereux par la chimiotherapie | |
| FR2662940A1 (fr) | Utilisation de derives de la tetrahydro isoquinoleine pour la preparation de medicaments anti-tumoraux, application a titre de medicaments de derives de la tetrahydro isoquinoleine et produits derives de cette structure. | |
| RU2084449C1 (ru) | 1-бензил-2-оксотриптамин гидрохлорид и его производные, обладающие гепатозащитной активностью | |
| CN111803489A (zh) | 含笑内酯及其衍生物在垂体腺瘤治疗中的应用 | |
| CN119080748A (zh) | 一种靶向brd7抑瘤蛋白的增稳剂及其在制备治疗实体肿瘤药物中的应用 | |
| US20040048808A1 (en) | Methods for inhibiting angiogenesis | |
| KR100360350B1 (ko) | 어포토시스억제제 | |
| EP0092226B1 (en) | Extract of plants of the family of hypoxidaceae for treatment of cancer | |
| US20100256230A1 (en) | 1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof | |
| WO2021120874A1 (zh) | 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用 | |
| KR19990034285A (ko) | 항암활성을 갖는 육두구 추출물 | |
| AU2021104207A4 (en) | Halloysite nanotube as a modified drug release carrier for 6-mercaptopurine | |
| RU2675237C1 (ru) | Соединение (6-{ [(1S)-1(5-фтор-4-оксо-3-фенил-3,4-дигидрохиназолин-2-ил)пропил]амино} -9Н-пурин-9-ил)метилацетат как ингибитор p110δ - дельта-изоформы фосфоинозитид-3-киназы (PI3K), способы его получения (варианты) и применения | |
| BE1028852B1 (fr) | PRODROGUE DU 5α-hydroxy-6β-[2-(1H-imidazol-4-yl) éthylamino]cholestan-3β-ol ET COMPOSITIONS PHARMACEUTIQUES LE COMPRENANT POUR UTILISATION DANS LE TRAITEMENT DU CANCER | |
| WO2019003237A1 (en) | INDOLYLKOJYL METHANE ANALOGUES, PREPARATION METHOD AND USE THEREOF AS INVASION INHIBITOR OF CANCER CELLS AND METASTASES | |
| RU2623034C1 (ru) | Противоопухолевое средство | |
| RU2145854C1 (ru) | Противоопухолевое средство | |
| JP2002521341A (ja) | 抗癌および抗炎症効果を有する牛糞抽出物およびその製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |